0.125
price up icon2.21%   0.0027
pre-market  Pre-market:  .11   -0.015   -12.00%
loading
AIM ImmunoTech Inc stock is traded at $0.125, with a volume of 223.64K. It is up +2.21% in the last 24 hours and down -7.41% over the past month. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.1223
Open:
$0.1232
24h Volume:
223.64K
Relative Volume:
0.23
Market Cap:
$8.59M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-0.2083
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-9.22%
1M Performance:
-7.41%
6M Performance:
-50.98%
1Y Performance:
-74.50%
1-Day Range:
Value
$0.1205
$0.1347
1-Week Range:
Value
$0.12
$0.1389
52-Week Range:
Value
$0.1105
$0.62

AIM ImmunoTech Inc Stock (AIM) Company Profile

Name
Name
AIM ImmunoTech Inc
Name
Phone
352 448 7797
Name
Address
2117 SW Highway 484, Ocala, FL
Name
Employee
24
Name
Twitter
@AIMImmuno
Name
Next Earnings Date
2024-12-15
Name
Latest SEC Filings
Name
AIM's Discussions on Twitter

Compare AIM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AIM
AIM ImmunoTech Inc
0.125 8.59M 202.00K -28.96M -21.85M -0.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

AIM ImmunoTech Inc Stock (AIM) Latest News

pulisher
03:00 AM

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo

03:00 AM
pulisher
Apr 01, 2025

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 31, 2025
pulisher
Mar 28, 2025

Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings Preview For AIM ImmunoTech - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Inc. (AIM) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan

Mar 27, 2025
pulisher
Mar 19, 2025

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World

Mar 18, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News

Mar 06, 2025
pulisher
Mar 05, 2025

Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Mar 04, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech appoints Chemerow as an Independent Director - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech Inc. Appoints Principal Investigator for Clinical Study Combining Ampligen and AstraZeneca's FluMist for Influenza Vaccine Development - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

AIM announces Paul Goepfert, MD, as the principal - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Could This $10M Avian Flu Vaccine Strategy Outperform Billion-Dollar mRNA Alternatives? - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech to Present at the Investor Summit in Philadelphia - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times

Feb 27, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Plans to Meet NYSE Compliance by 2026 Amid Cancer and Antiviral Drug Advances - HPBL

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Eyes a Resilient Comeback with Strategic Moves to Stay Afloat - Smartphone Magazine

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech gains NYSE compliance plan approval By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Biotech Trailblazer AIM ImmunoTech Charts a Resilient Path to Equity Compliance - Jomfruland.net

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech gains NYSE compliance plan approval - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Secures NYSE American Compliance Plan Approval – What It Means for Investors - HPBL

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance -February 26, 2025 at 01:37 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Inc. Receives Approval from NYSE American for Compliance Plan with Listing Standards - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Can AIM ImmunoTech Maintain NYSE Listing? Exchange Grants Rare 2-Year Extension - StockTitan

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Appoints David Chemerow to Board - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Former Comscore Executive Turn Around AIM ImmunoTech's Immuno-Pharma Ambitions? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

AIM Doses First New Subject in Phase 2 Study of Ampligen - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Hemispherx Biopharma stock hits 52-week low at $0.12 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Hemispherx Biopharma stock hits 52-week low at $0.12 - Investing.com India

Feb 25, 2025

AIM ImmunoTech Inc Stock (AIM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Cap:     |  Volume (24h):